Listen
ANORO (umeclidinium bromide / vilanterol), long-acting anticholinergic / beta 2-adrenergic agonist
RESPIRATORY MEDICINE - New medicinal product
Opinions on drugs -
Posted on
Mar 10 2017
Reason for request
Inclusion
No clinical benefit demonstrated relative to comparators in the treatment of symptoms of chronic obstructive pulmonary disease
- ANORO has Marketing Authorisation in continuous bronchodilator treatment to relieve symptoms of chronic obstructive pulmonary disease (COPD).
- Its clinical benefit is low in the absence of a clear demonstration of efficacy on trough FEV1, dyspnoea symptoms, reduction of exacerbations and quality of life compared to a long-acting beta-2-adrenergic agonist or anticholinergic taken alone.
- It is a second-line medicine in patients with moderate to very severe stage COPD in the event of insufficient response to a long-acting bronchodilator as a monotherapy
Clinical Benefit
| Moderate |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
